CRL vs FTRE
CRL: Charles River Laboratories is a global, non-clinical contract research organization that partners with life sciences companies to streamline drug discovery and development. FTRE: Fortrea is a dedicated global CRO focused on clinical trial execution and commercialization services to help biopharmaceutical companies bring new therapies to market.
Side-by-side fundamentals
| Metric | CRL | FTRE | Edge |
|---|---|---|---|
| Price as of 2026-08-06 close | $265.51 | $17.69 | |
| Market cap as of 2026-08-08 | $12.7B | $1.7B | |
| PEG as of 2026-08-08 | -0.21 | 0.45 | CRL lower |
| Net margin as of 2026-08-08 | -4.6% | -3.2% | FTRE higher |
| Gross margin as of 2026-08-08 | +34.5% | +19.3% | CRL higher |
| Operating margin as of 2026-08-08 | +1.8% | -0.4% | CRL higher |
| ROE as of 2026-08-08 | -5.7% | -15.5% | CRL higher |
| ROA as of 2026-08-08 | -2.5% | -3.1% | CRL higher |
| Debt / equity as of 2026-08-08 | 0.91 | 2.01 | CRL lower |
| Revenue growth (YoY) as of 2026-08-08 | +0.1% | -2.1% | CRL higher |
| Revenue CAGR (3y) SEC XBRL | +0.3% | -1.4% | CRL higher |
| Beta as of 2026-08-08 | 1.40 | 1.97 | |
| 1-year return as of 2026-08-06 close | +76.6% | +168.8% | FTRE higher |
Fundamentals: market data, as of 2026-08-08. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-06.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.